Literature DB >> 31945307

Reduced sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care.

Steven G Badman1, Sara F E Bell2, Judith A Dean2, Jime Lemoire3, Luke Coffey3, Joseph Debattista4, Andrew M Redmond5, Owain D Williams2, Charles F Gilks2, David M Whiley6.   

Abstract

Background The aim of this study was to compare the performance of pooled self-collected urogenital, pharyngeal and anorectal specimens to that of individual specimen results for the molecular detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) near the point of care (POC) for diagnostic sensitivity.
METHODS: Clients (mostly men who have sex with men) attending an urban community testing service and three sex-on-premises venues in Brisbane, Australia, were offered CT and NG testing by trained lay providers. Participants provided three self-collected specimens (urine, pharyngeal and rectal) for testing by GeneXpert (Cepheid, Sunnyvale, CA, USA). If any of the individual specimens from a participant were positive, all three specimens were pooled and retested.
RESULTS: Of the 388 participants who provided three individual anatomical specimens, 76 (19.6%) were found to be positive for CT and/or NG at one or more sites. The pooling approach failed to detect five CT rectal and four NG pharyngeal infections. The overall performance (sensitivity) of the pooling approach compared with individual specimen testing and Cohen's κ were 90.0% and 0.86 respectively for CT and 89.7% and 0.89 respectively for NG.
CONCLUSIONS: Reduced sensitivity was observed when using pooled specimens for the detection of CT and NG using GeneXpert near the POC, similar to results reported in laboratory-based CT and NG pooling studies. These data suggest specimen pooling is feasible near to the POC, potentially saving time and costs when screening at-risk populations for CT and NG. Our data also suggest a reduction in pooled urine could improve overall test sensitivity.

Entities:  

Year:  2020        PMID: 31945307     DOI: 10.1071/SH19028

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  6 in total

1.  A Population-Specific Optimized GeneXpert Pooling Algorithm for Chlamydia trachomatis and Neisseria gonorrhoeae To Reduce Cost of Molecular Sexually Transmitted Infection Screening in Resource-Limited Settings.

Authors:  Sarah Connolly; William Kilembe; Mubiana Inambao; Ana-Maria Visoiu; Tyronza Sharkey; Rachel Parker; Kristin M Wall; Amanda Tichacek; Eric Hunter; Susan Allen
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

2.  Point-by-Point Progress: Gonorrhea Point of Care Tests.

Authors:  Charlotte A Gaydos; Johan H Melendez
Journal:  Expert Rev Mol Diagn       Date:  2020-06-30       Impact factor: 5.225

3.  Pooled 3-Anatomic-Site Testing for Chlamydia trachomatis and Neisseria gonorrhoeae: A Systematic Review and Meta-Analysis.

Authors:  Jasmine Almeria; Joshua Pham; Keely S Paris; Karen M Heskett; Irvin Romyco; Claire C Bristow
Journal:  Sex Transm Dis       Date:  2021-12-01       Impact factor: 2.830

4.  Diagnostic accuracy of pooling urine, anorectal, and oropharyngeal specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae: a systematic review and meta-analysis.

Authors:  Lily Aboud; Yangqi Xu; Eric P F Chow; Teodora Wi; Rachel Baggaley; Maeve B Mello; Christopher K Fairley; Jason J Ong
Journal:  BMC Med       Date:  2021-11-25       Impact factor: 8.775

Review 5.  Chlamydia trachomatis as a Current Health Problem: Challenges and Opportunities.

Authors:  Rafaela Rodrigues; Carlos Sousa; Nuno Vale
Journal:  Diagnostics (Basel)       Date:  2022-07-25

6.  The Performance of Pooled 3 Anatomic Site Testing for Chlamydia trachomatis and Neisseria gonorrhoeae Among Men Who Have Sex With Men and Transgender Women.

Authors:  Claire C Bristow; Sanjay R Mehta; Martin Hoenigl; Susan J Little
Journal:  Sex Transm Dis       Date:  2021-10-01       Impact factor: 3.868

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.